All In Biotech

Drug Trial Radar · NCT00354081

WENBIT - Western Norway B Vitamin Intervention Trial

A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography

Last checked: Nov 20, 2026Latest source record: Jul 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,096 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,096

Actual

Start

Apr 1999

Primary completion

Jun 2007

Study completion Feb 2008

Sponsor

Lead sponsor
Haukeland University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Research Council of Norway; Norwegian Foundation for Health and Rehabilitation; Norwegian Heart and Lung Patient Organisation; The Royal Norwegian Ministry of Health; Locus for Homocysteine and Related Vitamins, University of Bergen, Norway; Locus for Cardiac Research, University of Bergen, Norway; Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway; Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
First posted
Jul 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PURPOSE OF STUDY Observational studies have demonstrated that elevated levels of plasma total homocysteine is a risk factor for cardiovascular disease. The purpose of this trial is to evaluate the clinical effects of homocysteine lowering treatment with B vitamins during 3-5 years follow-up of patients undergoing cardiac catheterization for suspected coronary artery disease (CAD). Special attention will be given to complication rates among patients needing subsequent percutaneous transluminal coronary angioplasty (PCI) or coronary artery by-pass grafting (CABG). HYPOTHESIS The primary hypothesis of this study is that, among patients with CAD, a daily supplement with B vitamins will reduce the risk for cardiovascular mortality and serious cardiovascular events with at least 20%. The secondary hypothesis of this study is that, among patients with CAD, a daily supplement with B vitamins will reduce the risk for total mortality, coronary events, cerebrovascular events and other cardiovascular events. The hypothesis will be tested for an effect of any of the treatments (folic acid / vitamin B12 or B6), and the effect will be evaluated according to initial total homocysteine levels and B vitamin levels as well as to the change in these levels after 1 and 6 months. The sample size has been calculated to 3088 patients using a two-sided chi-square test with significance 0.05 and at an 80% power level, presumed event rate of 22% over 4 years, and event rate reduction of 20%, adjusted for non-compliance/drop-out of 20%. STUDY DESIGN This is a controlled, double-blind two-centre trial with 3090 included men and women who underwent coronary angiography at Haukeland University Hospital or Stavanger University Hospital between April 1999 and April 2004. At baseline about 1300 patients underwent PCI and 600 underwent CABG. The patients were randomized into 4 groups in a 2 x 2 factorial design to receive one of the following four treatments: A, folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg per day; B, folic acid 0.8 mg plus vitamin B12 0.4 mg per day; C, vitamin B6 40 mg per day; D, placebo. The active drug and the placebo tablets had identical appearance and taste. Treatment was started as soon as the patients were randomized after the coronary angiography procedure. The patients have been undergoing interviews, clinical examination and blood-sampling at baseline, at follow-up after 1 month and 1 year, and at a final study visit. In addition, information on dietary habits was obtained from 2400 patients at baseline. Among 350 patients that have undergone PCI at baseline, a full clinical examination, blood sampling and repeat coronary angiography to assess re-stenosis has been performed about 9 (6-12) months after the PCI procedure. For these patients, angiograms suitable for quantitative coronary angiography (QCA) analysis have been obtained at the baseline and follow-up invasive procedures. The follow-up was terminated ahead of schedule in October 2005 due to lack of compliance of the participants caused by media reports from the NORVIT study (NCT00266487) on potential increased cancer risk associated by B vitamin supplementation. The patients had then been followed for 1.5 - 5 years. STUDY END POINTS Primary clinical endpoints during follow-up are all cause death, non-fatal acute myocardial infarction, acute hospitalization for unstable angina and non-fatal thromboembolic stroke (infarction). Secondary endpoints are fatal and non-fatal acute myocardial infarction (including procedure related myocardial infarction), acute hospitalization for angina, stable angina with angiographic verified progression, myocardial revascularization, fatal and non-fatal thromboembolic stroke.

Conditions

  • Coronary Artery Disease
  • Myocardial Infarction
  • Cerebrovascular Stroke

Interventions

  • folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)Drug

    folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day

  • folic acid, vitamin B12 (cyanocobalamin)Drug

    folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day

  • vitamin B6 (pyridoxine)Drug

    vitamin B6 40 mg, in a capsule, taken orally once a day

  • placeboDrug

    placebo, in a capsule, taken orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of all cause death, non-fatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and of non-fatal thromboembolic stroke (infarction)Time frame: During follow-up, 1.5-5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Cardiology, Stavanger University Hospital

    Stavanger, Norway

  • Department of Heart Disease, Haukeland University Hospital

    Bergen, Bergen, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.